Does the media refer more to OBIO or PRCT?

In the previous week, PROCEPT BioRobotics had 29 more articles in the media than Orchestra BioMed. MarketBeat recorded 35 mentions for PROCEPT BioRobotics and 6 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 1.29 beat PROCEPT BioRobotics' score of 0.24 indicating that Orchestra BioMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orchestra BioMed 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PROCEPT BioRobotics 8 Very Positive mention(s) 0 Positive mention(s) 25 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better earnings & valuation, OBIO or BVS?

Bioventus has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Orchestra BioMed $33.48M 9.30 -$52.70M -$0.85 N/A Bioventus $581.85M 2.00 $22.73M $0.77 17.97

Does the media favor OBIO or BVS?

In the previous week, Orchestra BioMed had 4 more articles in the media than Bioventus. MarketBeat recorded 6 mentions for Orchestra BioMed and 2 mentions for Bioventus. Orchestra BioMed's average media sentiment score of 1.29 beat Bioventus' score of 0.89 indicating that Orchestra BioMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orchestra BioMed 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OBIO or STAA?

In the previous week, Orchestra BioMed and Orchestra BioMed both had 6 articles in the media. Orchestra BioMed's average media sentiment score of 1.29 beat STAAR Surgical's score of 1.02 indicating that Orchestra BioMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orchestra BioMed 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive STAAR Surgical 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, OBIO or IRMD?

iRadimed has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Orchestra BioMed $33.48M 9.30 -$52.70M -$0.85 N/A iRadimed $83.81M 13.29 $22.48M $1.79 48.64

Is OBIO or IRMD more profitable?

iRadimed has a net margin of 26.70% compared to Orchestra BioMed's net margin of -184.60%. iRadimed's return on equity of 23.45% beat Orchestra BioMed's return on equity. Company Net Margins Return on Equity Return on Assets Orchestra BioMed -184.60% -149.61% -54.15% iRadimed 26.70% 23.45% 20.36%

Does the media favor OBIO or IRMD?

In the previous week, Orchestra BioMed had 1 more articles in the media than iRadimed. MarketBeat recorded 6 mentions for Orchestra BioMed and 5 mentions for iRadimed. iRadimed's average media sentiment score of 1.72 beat Orchestra BioMed's score of 1.29 indicating that iRadimed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orchestra BioMed 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iRadimed 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer NNNN or OBIO?

Orchestra BioMed has a consensus price target of $13.00, suggesting a potential upside of 150.97%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, analysts clearly believe Orchestra BioMed is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Orchestra BioMed 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has preferable earnings and valuation, NNNN or OBIO?

Anbio Biotechnology has higher earnings, but lower revenue than Orchestra BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 127.59 $6.40M N/A N/A Orchestra BioMed $33.48M 9.30 -$52.70M -$0.85 N/A

Orchestra BioMed (OBIO) Competitors

$5.18 +0.07 (+1.37%)

As of 08/28/2026 04:00 PM Eastern

Compare

OBIO vs. PRCT, BVS, STAA, IRMD, and NNNN

Should you buy Orchestra BioMed stock or one of its competitors? Orchestra BioMed's main competitors and comparable companies include PROCEPT BioRobotics (PRCT), Bioventus (BVS), STAAR Surgical (STAA), iRadimed (IRMD), and Anbio Biotechnology (NNNN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Orchestra BioMed compare to PROCEPT BioRobotics?

Orchestra BioMed (NASDAQ:OBIO) and PROCEPT BioRobotics (NASDAQ:PRCT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Orchestra BioMed has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, PROCEPT BioRobotics has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market.

53.2% of Orchestra BioMed shares are owned by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 7.5% of Orchestra BioMed shares are owned by company insiders. Comparatively, 4.0% of PROCEPT BioRobotics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

PROCEPT BioRobotics has a net margin of -32.53% compared to Orchestra BioMed's net margin of -184.60%. PROCEPT BioRobotics' return on equity of -30.62% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-184.60%	-149.61%	-54.15%
PROCEPT BioRobotics	-32.53%	-30.62%	-22.10%

Orchestra BioMed currently has a consensus target price of $13.00, indicating a potential upside of 150.97%. PROCEPT BioRobotics has a consensus target price of $28.00, indicating a potential upside of 34.42%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, equities analysts clearly believe Orchestra BioMed is more favorable than PROCEPT BioRobotics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
PROCEPT BioRobotics	2 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.19

Orchestra BioMed has higher earnings, but lower revenue than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$33.48M	9.30	-$52.70M	-$0.85	N/A
PROCEPT BioRobotics	$308.05M	3.87	-$95.57M	-$1.94	N/A

In the previous week, PROCEPT BioRobotics had 29 more articles in the media than Orchestra BioMed. MarketBeat recorded 35 mentions for PROCEPT BioRobotics and 6 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 1.29 beat PROCEPT BioRobotics' score of 0.24 indicating that Orchestra BioMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orchestra BioMed	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PROCEPT BioRobotics	8 Very Positive mention(s)	0 Positive mention(s)	25 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Orchestra BioMed beats PROCEPT BioRobotics on 9 of the 17 factors compared between the two stocks.

How does Orchestra BioMed compare to Bioventus?

Orchestra BioMed (NASDAQ:OBIO) and Bioventus (NASDAQ:BVS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

53.2% of Orchestra BioMed shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 7.5% of Orchestra BioMed shares are held by insiders. Comparatively, 33.5% of Bioventus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Orchestra BioMed had 4 more articles in the media than Bioventus. MarketBeat recorded 6 mentions for Orchestra BioMed and 2 mentions for Bioventus. Orchestra BioMed's average media sentiment score of 1.29 beat Bioventus' score of 0.89 indicating that Orchestra BioMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orchestra BioMed	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bioventus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bioventus has a net margin of 9.36% compared to Orchestra BioMed's net margin of -184.60%. Bioventus' return on equity of 28.08% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-184.60%	-149.61%	-54.15%
Bioventus	9.36%	28.08%	9.82%

Bioventus has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$33.48M	9.30	-$52.70M	-$0.85	N/A
Bioventus	$581.85M	2.00	$22.73M	$0.77	17.97

Orchestra BioMed presently has a consensus target price of $13.00, indicating a potential upside of 150.97%. Bioventus has a consensus target price of $16.80, indicating a potential upside of 21.39%. Given Orchestra BioMed's higher possible upside, research analysts clearly believe Orchestra BioMed is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Bioventus	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Orchestra BioMed has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, Bioventus has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market.

Summary

Bioventus beats Orchestra BioMed on 11 of the 16 factors compared between the two stocks.

How does Orchestra BioMed compare to STAAR Surgical?

Orchestra BioMed (NASDAQ:OBIO) and STAAR Surgical (NASDAQ:STAA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

STAAR Surgical has a net margin of 1.13% compared to Orchestra BioMed's net margin of -184.60%. STAAR Surgical's return on equity of 9.05% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-184.60%	-149.61%	-54.15%
STAAR Surgical	1.13%	9.05%	6.99%

53.2% of Orchestra BioMed shares are held by institutional investors. Comparatively, 96.7% of STAAR Surgical shares are held by institutional investors. 7.5% of Orchestra BioMed shares are held by company insiders. Comparatively, 39.9% of STAAR Surgical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Orchestra BioMed has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, STAAR Surgical has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

Orchestra BioMed has higher earnings, but lower revenue than STAAR Surgical. Orchestra BioMed is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$33.48M	9.30	-$52.70M	-$0.85	N/A
STAAR Surgical	$239.44M	4.63	-$80.45M	$0.07	315.86

In the previous week, Orchestra BioMed and Orchestra BioMed both had 6 articles in the media. Orchestra BioMed's average media sentiment score of 1.29 beat STAAR Surgical's score of 1.02 indicating that Orchestra BioMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orchestra BioMed	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
STAAR Surgical	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Orchestra BioMed presently has a consensus target price of $13.00, suggesting a potential upside of 150.97%. STAAR Surgical has a consensus target price of $28.40, suggesting a potential upside of 28.45%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, research analysts clearly believe Orchestra BioMed is more favorable than STAAR Surgical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
STAAR Surgical	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.08

Summary

STAAR Surgical beats Orchestra BioMed on 10 of the 16 factors compared between the two stocks.

How does Orchestra BioMed compare to iRadimed?

Orchestra BioMed (NASDAQ:OBIO) and iRadimed (NASDAQ:IRMD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

53.2% of Orchestra BioMed shares are owned by institutional investors. Comparatively, 92.3% of iRadimed shares are owned by institutional investors. 7.5% of Orchestra BioMed shares are owned by company insiders. Comparatively, 34.6% of iRadimed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

iRadimed has a net margin of 26.70% compared to Orchestra BioMed's net margin of -184.60%. iRadimed's return on equity of 23.45% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-184.60%	-149.61%	-54.15%
iRadimed	26.70%	23.45%	20.36%

iRadimed has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$33.48M	9.30	-$52.70M	-$0.85	N/A
iRadimed	$83.81M	13.29	$22.48M	$1.79	48.64

In the previous week, Orchestra BioMed had 1 more articles in the media than iRadimed. MarketBeat recorded 6 mentions for Orchestra BioMed and 5 mentions for iRadimed. iRadimed's average media sentiment score of 1.72 beat Orchestra BioMed's score of 1.29 indicating that iRadimed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orchestra BioMed	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iRadimed	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Orchestra BioMed presently has a consensus price target of $13.00, suggesting a potential upside of 150.97%. iRadimed has a consensus price target of $120.00, suggesting a potential upside of 37.82%. Given Orchestra BioMed's higher possible upside, equities analysts clearly believe Orchestra BioMed is more favorable than iRadimed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
iRadimed	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.80

Orchestra BioMed has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, iRadimed has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Summary

iRadimed beats Orchestra BioMed on 14 of the 17 factors compared between the two stocks.

How does Orchestra BioMed compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

Anbio Biotechnology has a beta of 5.4, indicating that its stock price is 440% more volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

In the previous week, Orchestra BioMed had 4 more articles in the media than Anbio Biotechnology. MarketBeat recorded 6 mentions for Orchestra BioMed and 2 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.44 beat Orchestra BioMed's score of 1.29 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Anbio Biotechnology	Positive
Orchestra BioMed	Positive

53.2% of Orchestra BioMed shares are owned by institutional investors. 7.5% of Orchestra BioMed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Orchestra BioMed has a consensus price target of $13.00, suggesting a potential upside of 150.97%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, analysts clearly believe Orchestra BioMed is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Orchestra BioMed	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Anbio Biotechnology has higher earnings, but lower revenue than Orchestra BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	127.59	$6.40M	N/A	N/A
Orchestra BioMed	$33.48M	9.30	-$52.70M	-$0.85	N/A

Anbio Biotechnology has a net margin of 0.00% compared to Orchestra BioMed's net margin of -184.60%. Anbio Biotechnology's return on equity of 0.00% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Orchestra BioMed	-184.60%	-149.61%	-54.15%

Summary

Anbio Biotechnology and Orchestra BioMed tied by winning 7 of the 14 factors compared between the two stocks.

Get Orchestra BioMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OBIO vs. The Competition

Export

Metric	Orchestra BioMed	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$307.14M	$5.78B	$7.23B	$12.94B
Dividend Yield	N/A	1.75%	2.54%	11.02%
P/E Ratio	-6.09	25.92	273.45	25.45
Price / Sales	9.30	44.08	621.81	95.39
Price / Cash	N/A	32.99	79.29	54.21
Price / Book	16.19	6.18	12.97	6.14
Net Income	-$52.70M	$149.01M	$3.48B	$348.86M
7 Day Performance	-3.36%	-0.24%	0.13%	-0.80%
1 Month Performance	36.32%	7.85%	8.37%	5.56%
1 Year Performance	89.74%	6.22%	24.55%	15.57%

Orchestra BioMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OBIO Orchestra BioMed	3.708 of 5 stars	$5.18 +1.4%	$13.00 +151.0%	+91.1%	$307.14M	$33.48M	N/A	4	News Coverage Positive News Gap Up
PRCT PROCEPT BioRobotics	3.6433 of 5 stars	$20.97 -2.9%	$28.00 +33.5%	-48.4%	$1.20B	$308.05M	N/A	430	Trending News
BVS Bioventus	4.5279 of 5 stars	$13.84 -1.7%	$16.80 +21.4%	+90.9%	$1.16B	$581.85M	17.97	1,200
STAA STAAR Surgical	3.8819 of 5 stars	$22.74 -1.9%	$28.40 +24.9%	-19.3%	$1.15B	$239.44M	327.12	1,211	Positive News
IRMD iRadimed	2.9763 of 5 stars	$87.34 -0.6%	$120.00 +37.4%	+19.2%	$1.12B	$83.81M	48.82	110	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OBIO) was last updated on 8/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Orchestra BioMed (OBIO) Competitors

OBIO vs. PRCT, BVS, STAA, IRMD, and NNNN

How does Orchestra BioMed compare to PROCEPT BioRobotics?

Summary

How does Orchestra BioMed compare to Bioventus?

Summary

How does Orchestra BioMed compare to STAAR Surgical?

Summary

How does Orchestra BioMed compare to iRadimed?

Summary

How does Orchestra BioMed compare to Anbio Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBIO vs. The Competition

Orchestra BioMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Orchestra BioMed (OBIO) Competitors

OBIO vs. PRCT, BVS, STAA, IRMD, and NNNN

How does Orchestra BioMed compare to PROCEPT BioRobotics?

Which has more volatility & risk, OBIO or PRCT?

Do institutionals and insiders believe in OBIO or PRCT?

Is OBIO or PRCT more profitable?

Do analysts recommend OBIO or PRCT?

Which has higher earnings & valuation, OBIO or PRCT?

Does the media refer more to OBIO or PRCT?

Summary

How does Orchestra BioMed compare to Bioventus?

Do institutionals & insiders believe in OBIO or BVS?

Does the media favor OBIO or BVS?

Is OBIO or BVS more profitable?

Which has better earnings & valuation, OBIO or BVS?

Do analysts prefer OBIO or BVS?

Which has more risk and volatility, OBIO or BVS?

Summary

How does Orchestra BioMed compare to STAAR Surgical?

Is OBIO or STAA more profitable?

Do insiders and institutionals have more ownership in OBIO or STAA?

Which has more volatility and risk, OBIO or STAA?

Which has higher valuation & earnings, OBIO or STAA?

Does the media favor OBIO or STAA?

Do analysts recommend OBIO or STAA?

Summary

How does Orchestra BioMed compare to iRadimed?

Do insiders and institutionals have more ownership in OBIO or IRMD?

Is OBIO or IRMD more profitable?

Which has better valuation & earnings, OBIO or IRMD?

Does the media favor OBIO or IRMD?

Do analysts recommend OBIO or IRMD?

Which has more volatility and risk, OBIO or IRMD?

Summary

How does Orchestra BioMed compare to Anbio Biotechnology?

Which has more risk and volatility, NNNN or OBIO?

Does the media refer more to NNNN or OBIO?

Do insiders and institutionals hold more shares of NNNN or OBIO?

Do analysts prefer NNNN or OBIO?

Which has preferable earnings and valuation, NNNN or OBIO?

Is NNNN or OBIO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBIO vs. The Competition

Orchestra BioMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools